KL-A167
Phase 3Small molecule
KL-A167 is one of 130 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 3.
3
Indications
6
Total Trials
3
Active Trials
129
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1QL1706
Qilu Pharmaceutical Co., Ltd.Phase 3
Iza-Bren
Bristol-Myers SquibbPhase 3
Paclitaxel or Nab-Paclitaxel
AstraZenecaPhase 3
KL-A167
SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Nasopharyngeal Carcinoma2 trials
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Active, not recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 3·NCT05294172·295 enrolled
Small Cell Lung Cancer1 trial
SKB500 Combinations in Patients With Small Cell Lung Cancer
Not yet recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT07296809·80 enrolled
Non-Small Cell Lung Cancer1 trial
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Recruiting·SSichuan Kelun Pharmaceutical Research Institute Co., Ltd.·Phase 2·NCT05351788·110 enrolled
Lymphoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KL-A167. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details